NCT05723276已完成不适用
Probing the Functional Magnetic Resonance Imaging Response to Psilocybin in Functional Neurological Disorder (PsiFUND)
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Change in functional connectivity in default mode network
研究概览
简要总结
The goal of this study is to learn about the brain network response in people who have functional neurological disorder who are administered with a single dose of the psychedelic psilocybin with therapeutic support.
The main question it aims to answer is:
Can the default mode network, a brain network thought to be relevent in FND, be modified by the administration of psilocybin based on functional magnetic resonance imaging before and after the dose?
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 25 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 25 - 60 years.
- •Fluent in the English language
- •A diagnosis of FND from a neurologist and/or neuropsychiatrist as per DSM-5 criteria
- •Moderate or severe symptoms (≥4 on Clinical Global Impression Severity (CGI-S) scale) which have been present for >12 months and have failed to respond to best available treatment.
- •Able to tolerate fMRI scanning procedures.
- •Failed to respond is defined as an inadequate response to a full course of FND-specific therapy, including psychological therapy (cognitive behavioural therapy) or physiotherapy. Either therapy must have been undertaken by a suitably trained expert in FND and must have been specifically targeted at FND symptoms.
排除标准
- •Diagnosis of severe depression (defined as meeting DSM-5 criteria) on the MINI 7.
- •Positive diagnoses on the MINI will be subject to confirmation at clinical interview by a psychiatrist.
- •Diagnosis of bipolar affective disorder (defined as meeting DSM-5 criteria for bipolar I or bipolar II) on the MINI 7.
- •Positive diagnoses on the MINI will be subject to confirmation at clinical interview by a psychiatrist.
- •Diagnosis of a psychotic disorder (defined as meeting DSM-5 criteria) on the MINI 7.0, EXCEPT substance/medication induced psychotic disorder where the duration was limited to the acute period of direct intoxication with the substance/medication. Positive diagnoses on the MINI will be subject to confirmation at clinical interview by a psychiatrist.
- •Diagnosis of drug or alcohol dependence disorder (defined as meeting DSM-5 criteria) on the MINI 7.
- •Positive diagnoses on the MINI will be subject to confirmation at clinical interview by a psychiatrist.
- •Diagnosis of a personality disorder (defined as meeting DSM-5 criteria) on the MINI 7.
- •Positive diagnoses on the MINI will be subject to confirmation at clinical interview by a psychiatrist.
- •Diagnosis of any dementia (defined as meeting DSM-5 criteria for any dementia disorder) based on clinical interview by a psychiatrist.
- •Diagnosis of any autistic spectrum disorder (defined as meeting DSM-5 criteria for any dementia disorder) based on clinical interview by a psychiatrist.
- •Diagnosis of any learning disability (defined as meeting DSM-5 criteria for any dementia disorder) based on clinical interview by a psychiatrist
- •Significant suicidal behaviour in past 12-months defined using the Columbia-Suicide Severity Rating Scale (C-SSRS) and confirmation based on clinical interview by a psychiatrist
- •Any other factor which would render the participant unsuitable for psilocybin and/or interfere with a supportive therapeutic relationship and/or preclude safe follow-up.
- •Those unable to give informed consent
- •Medical diagnosis incompatible with psilocybin treatment (see Section 8.2.1)
- •Inability to provide a screening blood sample, urine sample or electrocardiogram.
- •Biochemical abnormalities (defined as falling outside the normal reference range) as evaluated by a full blood count, full biochemistry profile and thyroid function tests. Biochemical abnormalities must also be determined as clinically significant by a medical doctor to fulfil the criterion for exclusion.
- •Electrocardiographic abnormalities, defined as any abnormality that is not normal sinus rhythm and determined as clinically significant by a medical doctor.
- •Women of childbearing potential not using contraception.
- •Pregnant or breast-feeding women.
- •Non-registration with a GP or failure to consent to sharing of the GP summary care record and any psychiatric assessments held.
- •Those enrolled in another clinical or research study.
- •Use of any psychedelic substances >2 times in past 12 months.
- •Any factor which would exclude the participant from magnetic resonance imaging (e.g., presence of metal)
研究组 & 干预措施
Study arm
Experimental
Psilocybin with therapeutic support
干预措施: Psilocybin (Drug)
结局指标
主要结局
Change in functional connectivity in default mode network
时间窗: One week prior dosing versus one week post dosing (intra-subject)
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
fMRI in Deep Brain StimulationChronic PainEpilepsyNCT03819738Universitaire Ziekenhuizen KU Leuven20
已完成
不适用
Functional Magnetic Resonance Imaging (fMRI) During Deep Brain Stimulation (DBS) to Treat Parkinson's DiseaseEssential TremorObsessive Compulsive DisorderDystoniaParkinson DiseaseNCT01809613Mayo Clinic88
招募中
不适用
fMRI for BPS: A Descriptive Study of Findings and SymptomsBladder Pain SyndromeNCT06294951RenJi Hospital120
招募中
不适用
Functional Brain Network Changes in Patients Undergoing Deep Brain Stimulation for Essential TremorEssential TremorNCT06293638The Cleveland Clinic55
招募中
不适用
Neural Bases of Social Cognitive Processing in Healthy IndividualsHealthy VolunteersNCT05774860Istituti Clinici Scientifici Maugeri SpA200